Wang DS - Search Results

1

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.

Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Lu Q, et al. Among authors: wang ds. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749. J Med Chem. 2005. PMID: 16107152

2

alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion.

Wang D, Chuang HC, Weng SC, Huang PH, Hsieh HY, Kulp SK, Chen CS. Wang D, et al. J Med Chem. 2009 Sep 24;52(18):5642-8. doi: 10.1021/jm9002457. J Med Chem. 2009. PMID: 19708661 Free PMC article.

3

Development of a novel class of glucose transporter inhibitors.

Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS. Wang D, et al. J Med Chem. 2012 Apr 26;55(8):3827-36. doi: 10.1021/jm300015m. Epub 2012 Apr 10. J Med Chem. 2012. PMID: 22468970 Free PMC article. Retracted.

4

Development of small-molecule cyclin D1-ablative agents.

Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS. Huang JW, et al. Among authors: wang ds. J Med Chem. 2006 Jul 27;49(15):4684-9. doi: 10.1021/jm060057h. J Med Chem. 2006. PMID: 16854074

5

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Kulp SK, et al. Among authors: wang ds. Clin Cancer Res. 2006 Sep 1;12(17):5199-206. doi: 10.1158/1078-0432.CCR-06-0429. Clin Cancer Res. 2006. PMID: 16951239 Retracted.

6

Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS. Yang J, et al. Among authors: wang ds, wang yc. J Med Chem. 2008 Apr 10;51(7):2100-7. doi: 10.1021/jm701212m. Epub 2008 Mar 13. J Med Chem. 2008. PMID: 18335975 Free PMC article.

7

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS. Lu YS, et al. Hepatology. 2007 Oct;46(4):1119-30. doi: 10.1002/hep.21804. Hepatology. 2007. PMID: 17654699

8

Development of novel adenosine monophosphate-activated protein kinase activators.

Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS. Guh JH, et al. J Med Chem. 2010 Mar 25;53(6):2552-61. doi: 10.1021/jm901773d. J Med Chem. 2010. PMID: 20170185 Free PMC article. Retracted.

9

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. Lin TY, et al. Blood. 2010 May 27;115(21):4217-25. doi: 10.1182/blood-2009-07-231985. Epub 2010 Mar 16. Blood. 2010. PMID: 20233974 Free PMC article.

10

Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression.

Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q, Chen CS. Chen CH, et al. J Biol Chem. 2011 Mar 25;286(12):9968-76. doi: 10.1074/jbc.M110.203240. Epub 2011 Jan 31. J Biol Chem. 2011. PMID: 21282102 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,051 results

Search Page